In this report, we describe our findings on the relationship between estradiol 16a-hydroxylation and mammary tumor incidence. A close correlation between the two has been demonstrated with 16-hydroxylation being elevated in strains with a high incidence of tumors, such as RIII and C3H, and low in strains with a low incidence of cancer, such as C57BL. The extent of reaction is highly reproducible and unaffected by age or presence of overt mammary tumors. Studies on the inheritance of estradiol 16a-hydroxylase showed that it is inherited as an autosomal dominant and is not correlated with estradiol 2-hydroxylase or androgen and progestin 16a-hydroxylases. In addition, the reaction was shown to be markedly enhanced by the presence of murine mammary tumor virus and diminished in the absence of the virus. These studies establish a relationship between genetics, hormonal factors, and murine mammary tumor virus, the three key factors in mammary tumorigenesis. disease, unless the increase was a consequence of the cancer itself. An animal model with spontaneous estrogen-mediated mammary tumors in which the extent of estrogen 16a-hydroxylation could be readily studied before and after tumor development would assist in choosing between the alternative hypotheses offered above. In addition, such a model would facilitate studies on the mechanisms by which this reaction is regulated and whether it affects the initiation or promotion of the disease. In this report, we describe our studies on estrogen metabolism in the murine mammary tumor model, which show that a close relationship between the extent of tumor incidence and 16a-hydroxylation of estradiol exists. Furthermore, we find that the presence of exogenous mouse mammary tumor virus (MMTV) increases 16a-hydroxylation of estradiol, providing a possible link between the viral and hormonal elements of mammary tumorigenesis in the mouse.Epidemiological evidence dating back to the observations of Beatson (1) provides a strong argument that endogenous estrogens participate in the etiology and progress of human breast cancer (2). Because of this, much effort has been directed to the identification of differences in the secretion and/or metabolism of estrogens in women with breast cancer, but the results obtained have been contradictory and the existence of such differences remains equivocal (3). A possible reason for this failure to discern a consistent difference is that breast cancer is a disease with a long latent period (4) and, consequently, the hormonal status at the time of diagnosis may not reflect that existing at the time of disease initiation. Clearly, secretion of estrogens is highly dependent on age and menopausal status and we have therefore sought to find a measure of estrogen metabolism that is not affected by age or menopausal stage and that will reflect metabolic status at the time of disease initiation. Using a radiometric procedure for measuring the enzymatic activity of the major pathways of the oxidative metabolism of estradiol, 17,3-ol oxidation, a...